1. Introduction
Leptin is a non-glycosylated hormone consisting of 167 amino acids whose existence was predicted for the first time in leptin deficient (ob/ob) and leptin receptor deficient (db/db) mice [1,2] and later described as the product of the obese (Ob) gene [3]. In vertebrates, leptin structures show differences in their primary amino acid sequences, but secondary and tertiary structures are similar [4], being alike to the long-chain helical cytokine family, which includes interleukin (IL) 6, IL-11, IL-12, G-CSF or oncostatin M, among others [5].
Leptin is mainly expressed in adipose tissue, but it has also been found in other tissues, such as the gastrointestinal system, the brain, or muscles [6]. In physiological conditions, leptin expression is regulated by cortisol [7], insulin [8], and IL-1b [9] during inflammation, and is an essential part of the healing process since it restores both physiological functions and homeostasis. Leptin plays a key role in inflammation due to a huge variety of metabolic effects, e.g., it increases both fatty acid oxidation [10] and glucose uptake [11]. However, inflammation sometimes takes a long period of time and could downregulate immune system functions, producing homeostatic changes and chronic pathological states, such as chronic inflammation [12]. In this context, leptin has a proinflammatory capacity, not only with a key role in obesity and food intake [13,14,15], but also in neuroendocrine regulation [16], reproduction [17,18] and diseases such as rheumatoid arthritis [19] and other autoimmune diseases [20].
Furthermore, leptin is well known to play a protumoral role, since it promotes angiogenesis, the proliferation, and survival of tumor cells, as well as the inhibition of apoptosis, leading to progression and metastasis [21]. In preclinical models, important findings related to both leptin and Ob-R levels have been found by using different strategies to overcome cancer, e.g., leptin receptor signaling has been shown to support cell metabolism in breast cancer [22], and vitamin D was found to mitigate breast tumor growth and dropped leptin levels in another study [23]. Moreover, high leptin and resistin levels impaired the therapeutic effects of dacarbazine in melanoma and their reduction improved the drug efficacy [24], which supports the importance and influence of leptin in obesity-associated conditions [25].
Conversely, leptin has been shown to reverse the immunosuppressive effects of acute starvation in mice [26]. In line with this, novel aspects have been reported in cancer. For example, leptin had antitumoral functions in human pancreatic cancer cell lines [27]. Recently, obese patients have been shown to obtain better responses to cancer immunotherapies [28,29,30], that may be related to leptin levels. For those reasons, the purpose of this article is to review the available literature concerning the relationship between leptin and chronic inflammation in cancer and the role of leptin as both a bad and good actor in the disease to better understand the possible dual effect of this hormone.
2. Literature Search
This literature review is the result of the study and analysis of information obtained on the relationship between leptin and cancer, approaching the role of obesity, inflammation, and immunotherapies in the disease, in the last decades. The literature search was conducted using the PubMed electronic database. The descriptors employed, being collated according to the MeSH and DeCs thesauri, were: leptin, obesity, inflammation, cancer, immunotherapy, treatment, immune system. Then, different search strategies were elaborated making use of quotation marks, truncations, and the Boolean operators AND and OR. Our search term for the PubMed database was as follows: leptin AND obesity, (leptin OR obesity) AND cancer, (leptin OR obesity) AND treatment AND cancer, (leptin OR obesity) AND immunotherapy, (leptin OR obesity) AND immune system, obesity AND immune system AND immunotherapy, (leptin OR obesity) AND inflammation, immune system AND inflammation, cancer AND inflammation, (immunotherapy OR treatment) AND inflammation AND cancer. We included research articles, meta-analysis, and reviews that met our search terms, published in the last decades, and written in English. We excluded articles and reviews with irrelevant information according to the points discussed in this review, as well as books and documents.
3. Role of Leptin in Inflammation
3.1. Leptin Receptors and Leptin Signaling Pathways
Leptin presents pleiotropic effects due to the huge variety of leptin receptors (known as Ob-R or LEPR), which belong to the class I cytokine superfamily [31,32], differing from each other in the lengths of their cytoplasmic regions and named Ob-Ra, Ob-Rb, Ob-Rc, Ob-Rd, Ob-Re and Ob-Rf. Short leptin isoforms (Ob-Ra, Ob-Rc, Ob-Rd, and Ob-Rf) can bind Janus kinases (JAK) and activate other signal transduction cascades, the soluble isoform (Ob-Re) is able to regulate leptin levels in serum, and the long leptin isoform (Ob-Rb) can fully transduce activation signals into cells via JAK2/signal transducer and activator of transcription (STAT) 3, mitogen activated protein kinase (MAPK)/extracellular-signal-regulated kinase (ERK) 1/2 or phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathways [33,34]. Ob-Rd and Ob-Rf have only been described in mice and rats, respectively [35].
3.2. Leptin, Inflammation, and Immune System
One of the pleiotropic effects of leptin involves the immunometabolism. Adipose tissue plays an important role in both energetic balance and storage of energy and, depending on the availability of energy, can limit or promote biological responses, such as the activation of the immune system to fight against infections [36]. Adipose tissue is also involved in inflammatory conditions by releasing hormones, anti-inflammatory, and proinflammatory factors, including leptin or adiponectin [37,38]. Leptin acts as a proinflammatory mediator in obesity-associated immune-metabolic disorders, such as diabetes, cardiovascular or autoimmune diseases, and cancer [12] by regulating hematopoiesis, lymphopoiesis, and myelopoiesis [39,40] at the development, proliferation, antiapoptotic, maturation and activation levels [41,42].
Ob-R expression is found in immune cells [36], thus leptin is involved in inflammatory/immune-related processes, e.g., by stimulating the proliferation of circulating monocytes [43]. In polymorphonuclear cells, leptin inhibits apoptosis [44,45], promotes chemotaxis [46,47], and improves the expression of CD11b via monocytes by releasing TNF-α [48], as well as stimulating the production of reactive oxygen species (ROS) [49]. Specifically in eosinophiles, leptin could suppress Intercellular Adhesion Molecule 3(ICAM-3) and enhances the expression of surface markers (e.g., ICAM-1 and CD18), and inflammatory cytokines such as IL-1β, IL-6, or IL-8 [50]. Leptin also upregulates the expression of CD63 in basophils and allows the production of type 2 cytokines such as IL-4 or IL-13 [51], which play an important role in some types of cancer [47].
In mast cells, leptin also acts as a chemoattractant and provokes the generation of histamine, cysteinyl leukotrienes, CCL2 or ROS [52], as well as causing an eosinophilic inflammation through the activation of mast cell secretory activity mediated by TNF-a, CCL5 or PGD2 [53]. Moreover, leptin-deficient mast cells take part in anti-inflammatory processes [54]. On the other hand, leptin has been described as a critical regulator for NK cell development and activation [55], since its impact on the NK immunomodulatory cytotoxicity and cytokine secretion seems unclear [56,57]. Additionally, leptin leads dendritic cell (DC) differentiation and survival [58] and helps to improve both the activation and proliferation of CD4+ and CD8+ T cells [59,60], as well as promoting Th17 differentiation [61] and Th2 responses [62]. By contrast, this hormone reduces the levels of regulatory T cells (Tregs) [63,64] and induces immunosenescence in B cells, decreasing the production of antibodies [65].
4. Role of Inflammation in Cancer
Inflammation is a protective response for affected tissues, that consists of the recruitment of leukocytes and plasma proteins, and causes vascularization, phagocytosis of debris and pathogens, as well as the production of proinflammatory signals such as IL-6, TNF-α or IFN-γ to recruit other immune cells. Transcriptional factors, peptides, chemokines, enzymes, lipids, and coagulation factors also take part in inflammatory processes. Once the response is finished favorably, anti-inflammatory signals (IL-10, IL-37 or TGF-β, among others) are secreted to shift the activity of the immune cells [12].
Inflammation can be developed by a huge variety of diseases, including obesity, hyperglycemia, and excessive lipid accumulation, which can promote different types of cancers [25,66,67] by releasing several factors such as ROS, TNF-α, IL-1, IL-6, IL-8, COX2, iNOS, and chemokines, among many others [68]. The inflammatory process affects during all cancer stages: In the first step, tumor initiation is produced not only by mutations and epigenetic alterations, but also by inflammatory mediators (e.g., NF-κB or STAT3 signaling) that cause tumors to be clinically evident. In the next step, cancer cells will expand until progression and metastasis. During this process, inflammatory factors such as NF-κB, IL-6 or IL-17 again act and serve like growth factors for tumor promotion, shaping cell plasticity within the TME. Later, cancer cells will spread and invade other tissues, a process in which proinflammatory molecules (e.g., TNF-α, IL-1β, or IL-11) participate to drive clonal selection of the most malignant cell clones and to recruit TGF-β and immune cells such as myeloid-derived suppressor cells (MDSCs), Tregs or M2 macrophages, that suppress T cell-mediated immune responses. Adhesion molecules and integrins (e.g., VCAM-1 and ICAM-1), produced by proinflammatory cytokines, and inflammatory cells (neutrophils and monocytes) also facilitate metastasis promoting intra- and extravasation [69].
In relation to the clinical perspective, there is consistent evidence that higher BMI is associated with increased risk of cancer despite the limitations of epidemiologic studies. Considering only obesity conditions (BMI ≥ 30 kg/m2), relative cancer risk was increased 1.2 to 1.5 times in multiple myeloma, from 1.5 to 1.8 in colon, gastric cardia, liver, gallbladder, kidney and pancreatic cancer, 4.8 times in esophageal adenocarcinoma, and from 2.5 to 7.1 in endometrial cancer. In addition, relative risk was increased approximately 1.1 per 5 BMI units in postmenopausal breast cancer patients [70]. For these reasons, how obesity affects outcomes in cancer is a key point to identify valid doses and treatments. There are no specific recommendations for the management of obese patients. Guideline recommendations are full weight-based chemotherapy (CT) doses [71] but, due to drug cytotoxicity and obesity-related comorbidities, obese patients can also receive CT doses based on their ideal body weight [72]. However, reductions in CT doses have been reported to be associated with increased rates of disease recurrence and mortality [73]. However, obese patients commonly present lower grades of cytotoxicity using CT compared with radiotherapy (RT) [74] and have more complications and inferior outcomes [75,76,77]. RT also alters and damages subcutaneous adipose tissue, contributing to metabolic dysfunction, which could be harmful for obese cancer patients [78].
5. Role of Leptin as a Bad Actor in Cancer
Over the last decades, the discovery of leptin and its receptors and their relationship with obesity and inflammation has led the possibility of new research avenues to help better understand the behavior of many diseases, including cancer. Nakao et al. (1998) described for the first time the role of leptin as a growth factor in malignant diseases by identifying Ob-R in leukemic blast cells from human samples [79].
Leptin could inhibit T cell responses by modulating both tumor cells and the TME. In obese individuals, this adipokine induces macrophages into their M2 phenotype [80], which is predominant in tumor-associated macrophages (TAMs) and plays a critical role in the initiation and progression of tumors [81]. In addition, leptin indirectly improves the role of MDSCs, a heterogeneous population of immature myeloid cells accumulated in the TME due to altered hematopoiesis, which includes granulocytic (G-MDSCs) and monocytic (M-MDSCs) precursors [82]. Leptin enhances MDSC functions via IFN-γ, which in turn is produced by leptin and regulates the checkpoint inhibitor PD-L1, causing T cell apoptosis [83]. Moreover, Ob-R blockade has been shown to decrease circulating MDSCs in breast cancer 4T1 tumor-bearing mice with a high fat diet [84].
5.1. Major Tumors Associated with Obesity and Leptin
Breast cancer (BC) was the most common diagnosed type of cancer worldwide during 2020 and the main cause of cancer death in the female population [85]. The relationship between obesity and BC is already established due to the complications related to surgery, radiation, and chemotherapy, with worst disease-free survival (DFS) and overall survival (OS), and an increased risk for local recurrence in female obese patients compared with their normal-weight counterparts [86] and the increased risk to develop estrogen receptor (ER)-positive BC in postmenopausal women [87,88].
Pathophysiological mechanisms remain unclear, but there are many factors involved in the association between obesity and BC, such as chronic subclinical inflammation, sex hormone deregulation, insulin/IGF-1 pathways, or the secretion of different adipokines like leptin [25]. Although some studies did not found association between leptin and BC [89,90], circulating leptin or its gene expression has been widely correlated with BC risk and progression, as well as proliferation and survival of BC cells [91,92,93,94,95,96,97,98,99,100]. Besides, leptin immunostaining has been proposed as a useful technique by supporting the identification of histotype, stage, grade, lymph node involvement, relapse, and prognosis in BC [101]. Moreover, some studies have suggested that a lower adiponectin/leptin ratio could be established in female obese patients [102,103] since low levels of the adipokine adiponectin in serum have been found to be correlated with BC risk [104]. Therefore, leptin and its receptors could be promising therapeutic targets to overcome tumor immunosuppression in the disease [105,106,107].
Colorectal cancer (CRC) is also attributed to overweight and obesity [108] and available data suggest that CRC risk is positively correlated with many factors, including metabolic syndrome [109] or leptin levels [110]. Some studies reported no associations between high serum leptin levels and CRC [111,112], but the majority described the overexpression of both leptin and Ob-R correlated with tumor progression [113,114,115,116,117]. Leptin was suggested to be a prognostic factor in CRC after analyzing survival distributions by using clinicopathological variables (tumor size, lymphovascular invasion, distant metastasis, local recurrence, and tumor relapse) in positive leptin immunostaining CRC [118]. Even leptin gene variants could exhibit sex-specific associations with CRC risk [119]. Moreover, serum leptin levels have been demonstrated to decrease following colectomy, supporting the association between leptin and CRC [120], thus suggesting leptin/Ob-R as a good target in the prevention and treatment of CRC, especially for obese patients [121].
Obesity and serum leptin are also a strong risk factors for Barrett’s esophagus [122], a precursor lesion in esophageal carcinoma [123]. Leptin and Ob-R expression has been found to play carcinogenic roles [124], since its binding activates the Akt signaling pathway in esophageal cancer cells via multiple atorvastatin sensitive small GTPases, leading to the growth and antiapoptosis of cancer cells [125]. Tumor leptin expression has also been related with chemotherapy resistance in gastro-esophageal adenocarcinomas, suggesting that leptin expression is potentially useful as a predictive marker of resistance to cytotoxic chemotherapy, and a prognostic marker independent of therapy in gastro-esophageal adenocarcinoma [126].
Circulating leptin levels or leptin/Ob-R expression also promote both the survival and proliferation of tumor cells in other types of cancer. For instance, leptin increases the risk of endometrial cancer [127], independently of the obese status of patients, indicating that leptin may be involved in the endometrial carcinogenesis by other pathways [28]. In hepatocellular carcinoma (HCC) there are risk factors potentially linked to leptin (e.g., chronic hepatitis B, chronic hepatitis C, alcohol consumption, aflatoxins, and the nonalcoholic fatty liver disease) [128]. Besides, leptin takes part in angiogenesis and is considered to increase HCC risk and progression [129,130]. High leptin expression has also been found in pancreatic cancer [131,132], renal cell carcinoma [133], prostate cancer [134,135,136,137], ovarian cancer [138,139,140], bladder cancer [141,142], or gallbladder cancer [143]. Figure 1 shows some of the most common types of cancer associated with high leptin levels.
5.2. Mechanistic Studies
Cancer progression involves tumor initiation and growth, invasion, and metastasis. Those steps include interactions with stromal tumor components [144], such as fibroblasts, endothelial cells, immune cells, and adipocytes. The mechanisms that associate obesity and cancer as they relate to leptin are still elusive [145] and, specifically, the pathological mechanisms of leptin to be associated with poor prognosis in cancer are still unclear [21].
Leptin receptors are products of a single Ob-R [146] and its binding to leptin, explained in Section 3.1., promotes the expression of antiapoptotic proteins (e.g., X-linked inhibitor of apoptosis protein (XIAP)), systemic inflammation (e.g., IL6), angiogenic factors (e.g., VEGF) and hypoxia inducible factor-1α (HIF-1α), which promotes cancer cell survival, proliferation, and migration [147]. In line with this, leptin could play a role in vascular remodeling in hypoxia conditions through HIF-1α in human adipocytes and fibroblasts, as occurs in solid tumors [148]. Leptin can regulate angiogenesis via VEGF and IL-6, and fibroblast growth factor (FGF) 2, suppresses apoptosis through a Bcl-2-dependent mechanism and acts as a mitogen or migration factor for many different cell types, including cancer cells, as well as sustaining the recruitment of monocytes and macrophages, that allow leptin to shape the TME [149]. Moreover, leptin signaling may promote oncogenesis through the promotion of the cancer stem cell phenotype [150].
The potential role of leptin in tumor evasion and metastasis was also explained by different mechanisms that involve tumor progression and migration, including not only signaling pathways, but also cancer-associated fibroblasts, VEGF and TAMs, among many others [21]. In addition, the binding leptin/Ob-Rb has been demonstrated to induce cancer progression via extracellular matrix-cell interactions, and epithelial−mesenchymal transition, an important step during metastasis to transform epithelial cells into mesenchymal cells [151].
6. Role of Leptin as Good Actor in Cancer
Obesity has also been shown to play a favorable role in tumorigenesis and has been associated with better outcomes in cancer [29], suggesting the existence of what we already know as the “obesity paradox” [152,153], which is very similar to the phenomenon observed in other pathological conditions, such as cardiovascular disease [154]. The reasons for this positive association remain unknown. Most of studies analyze overweight by using BMI, although this parameter may also be increased due to the existence of protective muscle mass [155]. In addition, adipose tissue in overweight cancer patients may represent an energy store that could be used to allow a longer survival time during the disease [25]. The obesity paradox has been established in many malignancies such as lung cancer [156,157,158], renal cell carcinoma [159,160,161,162], Hodgkin and non-Hodgkin lymphoma (including aggressive B-cell lymphomas) [163,164,165], melanoma [28,166,167], acute myeloid leukemia [168], CRC [169,170,171,172,173], or HCC [174]. In this regard, a meta-analysis of 6,320,365 patients found a negative association between obesity and lung cancer, renal cell carcinoma, and melanoma, suggesting the protective role of obesity [175]. Moreover, BMI could be a useful predictive tool in combination with the anti-PD-1/PD-L1 immune checkpoint [30]. However, leptin was not measured in those studies.
The first inhibitory effect of leptin treatment in human cancer cell lines was reported in Mia-PaCa and PANC-1 pancreatic cells [27]. In addition, some studies have communicated lower serum leptin levels in premenopausal BC patients compared with healthy controls and an inverse association between serum leptin levels and BC risk [176,177]. Leptin was also correlated with better prognosis in CRC patients [178] and inhibited in vitro HCC cell growth via the p38-MAPK-dependent signaling pathway [179]. Moreover, low leptin levels have been correlated with pancreatic cancer [180,181]. Taking all these results together, we suggest the name of “leptin paradox” to explain the dual role of leptin in cancer, in a similar way to obesity. Reviewed articles in which the obesity paradox is involved in cancer and others in which leptin has been a good actor in the disease are shown in Table 1.
7. Clinical Applications of Leptin in Cancer
Leptin treatments have been established in some types of diseases. For example, metreleptin has been demonstrated to work in patients with lipodystrophy, hypothalamic amenorrhea, and congenital leptin deficiencies [183,184] by binding Ob-R and activating the JAK/STAT signaling pathway [185]. The combination of leptin plus amylin may be used in obese patients [186] since amylin enhances leptin signaling in both leptin-sensitive and leptin-resistant subjects [187]. Moreover, Leptin has been used as a mucosal vaccine adjuvant against Rhodococcus equi in mice [188].
However, leptin treatments have not yet been fully applied in cancer because the mechanisms that involve leptin in those malignancies remain unknown, especially since the dual role of leptin in carcinogenesis has been suggested. In recent years, immunotherapies have revolutionized the field of oncology [189] by enhancing the immune system functions to fight against tumor cells, thus improving clinical outcomes in different types of cancer [190]. In this regard, Rivadeneira et al. (2019) identified leptin as a potent metabolic reprogramming agent that supported antitumor responses in aggressive melanomas [182]. They demonstrated that the T cell function in tumor-bearing mice enhances antitumor response compared with an oncolytic control by designing an oncolytic virus to express leptin, as well as promoting memory responses in the oncolytic virus-induced immune infiltrate.
Leptin may improve the immunotherapic action since this adipokine has been shown to regulate both innate and adaptive responses. Leptin may increase the cytotoxicity of NK cells [191], which have been demonstrated to develop a potent cytolytic activity against tumors [192]. Leptin has also been reported to stimulate the proliferation of T cells in vitro [193], as well as activating DC [192], thus promoting the cancer-immunity cycle [194]. Moreover, leptin deficiency has been associated with low levels of blood CD4+ T cells, which were reversed by using recombinant human leptin [195]. This adipokine could also enhance the proliferation of B cells and its activation to secrete cytokines [191]. Importantly, leptin has been shown to reduce the development of Tregs [191,196], which have been associated with poor prognosis and low survival rates in many types of malignancies, including breast [197], ovarian [198], prostate [199] or lung cancer [200], among many others.
8. Concluding Remarks and Future Perspectives
We strongly believe in the great value of leptin as a potential biomarker not only in cancer, but also in many other diseases, since there are a wide variety of studies supporting and demonstrating this idea, including those of our research group. However, it is important to know that many limitations exist, despite the vast literature available concerning to the role of both obesity and leptin increasing cancer risk and acting as promoters of tumor development and progression. In this sense, pathophysiological mechanisms are not entirely clear, since obesity and inflammation are influenced not only by leptin, but also by many other factors [68,201,202]. Moreover, the mechanisms whereby obesity and leptin behave as good actors in cancer also remain unknown.
Nevertheless, evidence has suggested the beneficial role of obesity, which is known as the “obesity paradox”. In the same line, some studies have shown that circulating leptin levels or leptin gene expression have been negatively correlated with cancer risk or associated with better prognosis by inhibiting tumor cell growth, e.g., Rivadeneira et al. (2019) added leptin in an immunotherapic oncolytic virus in melanoma-bearing mice, with promising results [182]. The beneficial role of leptin leads us to think the existence of what we have called the “leptin paradox”. Since leptin levels are demonstrated to be dependent on the amount of adipose tissue, we believe that the “leptin paradox” could mediate the “obesity paradox”, which means that better clinical outcomes in cancer patients with higher BMI may result from the beneficial effects of leptin. Therefore, we highlight the following future steps in this field: (1) It would be interesting to analyze blood leptin levels and/or leptin/Ob-R gene expression (and not only BMI) in obese cancer patients as both predictive and prognostic clinical biomarkers, paying special attention to those patients with better outcomes, and elucidate whether better responses to immunotherapies are caused in whole or in part by leptin and its receptors, and (2) further research is also needed to fully understand the complete mechanisms by which leptin behaves as both bad and good actor, because it could lead to the design of novel therapeutic strategies to inhibit or stimulate leptin signaling, whose evaluations could be interesting in the high-risk obese populations.
Funding
This research was funded by: Asociación Lazo Rosa; Asociación Verenia Sta Agueda de Brenes; Asociación Cambia el Guión.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
Not applicable.
Conflicts of Interest
The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figure and Table
Table 1
Reviewed studies in which obesity plays a favorable role in cancer and those in which leptin behaves as a good actor.
| Type of Cancer | Type of Study | References | Was Leptin Analyzed? | Was Leptin a Good Actor? |
|---|---|---|---|---|
| Breast | Humans | [176] | Yes | Yes * |
| Humans | [177] | Yes | Yes | |
| Pancreatic | Cell line | [27] | Yes | Yes |
| Humans | [180] | Yes | Yes | |
| Humans | [181] | Yes | Yes | |
| Melanoma | Humans | [166] | No | - |
| Humans | [30] | No | - | |
| Mice | [182] | Yes | Yes | |
| Humans | [175] | No | - | |
| Colorectal | Humans | [178] | Yes | Yes |
| Humans | [169] | No | - | |
| Humans | [170] | No | - | |
| Humans | [171] | No | - | |
| Humans | [172] | No | - | |
| Humans | [173] | No | - | |
| Renal | Humans | [159] | No | - |
| Humans | [160] | No | - | |
| Humans | [28] | No | - | |
| Humans | [162] | No | - | |
| Humans | [30] | No | - | |
| Humans | [175] | No | - | |
| Lung | Humans | [156] | No | - |
| Humans | [157] | No | - | |
| Humans | [30] | No | - | |
| Humans | [158] | No | - | |
| Humans | [175] | No | - | |
| Hepatocellular | Cell line | [179] | Yes | Yes |
| Humans | [174] | No | - | |
| Lymphomas | Humans | [163] | No | - |
| Humans | [164] | No | - | |
| Humans | [165] | No | - | |
| Myeloid leukemia | Humans | [168] | No | - |
| Others ** | Humans | [30] | No | - |
* No after adjustment of other risk factors included in the analysis. ** Types of cancer not specified in the reference.
© 2021 by the authors.
Details
1 Department of Medical Biochemistry and Molecular Biology, and Immunology, School of Medicine, Virgen Macarena University Hospital, University of Seville, 41009 Seville, Spain;
2 Urology Service, Virgen Macarena University Hospital, University of Seville, 41009 Sevilla, Spain;
3 Medical Oncology Service, Virgen Macarena University Hospital, University of Seville, 41009 Sevilla, Spain;